Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744209 · ClinicalTrials.gov registry record
Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 17
- Enrollment target
NCT02744209: Clinical Trial study, sponsored by Mayo Clinic.
NCT02744209 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744209 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treated with Pembrolizumab.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744209
The ClinicalTrials.gov registry entry for NCT02744209 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02744209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744209 about?
NCT02744209 is a clinical study titled "Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients". This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treat...
What is the current status of trial NCT02744209?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2016-04. Estimated completion is 2019-01.
Who is sponsoring clinical trial NCT02744209?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.